<DOC>
	<DOCNO>NCT00969033</DOCNO>
	<brief_summary>The purpose study determine effect CS-1008 combination irinotecan compare irinotecan alone Progression-Free Survival ( PFS ) subject metastatic advanced colorectal cancer ( CRC ) fail oxaliplatin-based first-line treatment .</brief_summary>
	<brief_title>CS-1008 Used With Irinotecan Versus Irinotecan Alone Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm CRC metastatic failure oxaliplatinbased firstline treatment . At least 18 year age . ECOG performance status = &lt; 1 . Measurable disease base RECIST criterion . Adequate organ bone marrow function evidence : Hemoglobin &gt; = 9.0 g/dL ( may transfuse level ) Absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L Platelet count &gt; = 100 x 109/L Serum creatinine = &lt; upper limit normal ( ULN ) creatinine clearance &gt; 50 mL/min AST &lt; = 2.5 x ULN subject liver metastasis &lt; = 5.0 x ULN subject liver metastasis Total bilirubin &lt; 1.5 x ULN Men woman childbearing potential must willing consent use effective contraception ( e.g. , hormonal contraceptive , bilateral tubal ligation , barrier spermicide , intrauterine device ) treatment 3 month thereafter . All female subject childbearing potential must negative pregnancy test ( serum urine ) result within 7 day initiate study treatment . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date IEC/IRB approve ICF performance study specific procedure test . Subjects must willing able comply schedule visit , treatment plan , laboratory test , study procedure . Anticipation need major surgical procedure radiotherapy ( RT ) study . Treatment chemotherapy hormonal therapy , RT , minor surgery , investigational agent within 4 week study enrollment . Treatment nitrosoureas , mitomycin C , immunotherapy , biological therapy , major surgery within six week prior study enrollment . St John 's Wort within 2 week prior study enrollment study . History follow condition within 6 month study enrollment : Clinically significant myocardial infarction severe/unstable angina pectoris New York Heart Association ( NYHA ) class III IV congestive heart failure ( Section 17.2 ) Clinically significant cerebrovascular accident , transient ischemic attack pulmonary embolism Clinically significant pulmonary disease ( e.g. , severe chronic obstructive pulmonary disease asthma ) Presence follow : Symptomatic brain metastasis ; uncontrolled seizure disorder ; spinal cord compression ; carcinomatous meningitis . Clinically significant active infection require antibiotic therapy Human Immunodeficiency Virus ( HIV ) positive subject receive antiretroviral therapy . History malignancy CRC , unless expectation malignancy cure , tumor specific treatment malignancy administer within previous 5 year . Exceptions non melanotic cancer skin adequately treat carcinoma cervixinsitu . Previous treatment CS 1008 , agonistic DR5 antibody agent , TRAIL agent . History active chronic inflammatory bowel disease and/or bowel obstruction within last 3 month . Pregnant breast feeding . Known history hypersensitivity reaction irinotecan one excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>